With the outbreak of COVID-19 in the Chinese city of Wuhan, infection prevention and control has become critical. Since 2006 antibodies-online.com serves Scientists and Research Institutions around the globe. To support SARS-CoV-2 research we put together a large collection of antibodies against different SARS-CoV-2 targets. Products for spike protein, membrane protein, envelope protein, nucleocapsid protein and non structural proteins are available. These antibodies can be used for detection of the virus in a variety of applications including IHC, ELISA, WB, IF staining. We also offer a set of neutralizing antibodies based on clone CR3022. Discover our SARS-CoV-2 antibody portfolio below.
Featured SARS-CoV-2 Antibodies used in Current Research
SARS-CoV-2 Spike Antibodies (S1, S2)
The SARS-CoV-2 spike protein protrudes from the envelope of the virion and plays a pivotal role in the receptor host selectivity and cellular attachment. Strong scientific evidence showed that SARS and SARS-CoV-2 spike proteins interact with angiotensin-converting enzyme 2 (ACE2).(1)
Below you will find a selection of our SARS-CoV-2 spike protein antibodies. Click on the links to see more details. See neutralizing S-protein antibodies based on clone CR3022
SARS-CoV-2 Nucleocapsid Antibodies
The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. After infection, the N protein enters the host cell together with the viral RNA to facilitate its replication and process the virus particle assembly and release. SARS-CoV-2 N protein contains two distinct RNA-binding domains (NTD and CTD) linked by a poorly structured linkage region containing a serine/arginine-rich (SR-rich) domain. (2) Below you will find a selection of our CoV SARS-CoV-2 nucleocapsid protein antibodies.
Rabbit Monoclonal SARS-CoV-2 N-Protein Antibodies
Rabbit monoclonals offer an improved immune response to small epitopes and a better response to mouse antigens. They give a better reaction to antigens than those from rodents such as mice. Because of their advantages rabbit monoclonal antibodies are becoming more preferred in research and clinical applications.
SARS-CoV-2 N-Protein Antibodies
SARS-CoV-2 Envelope Protein Antibodies
The E protein is the smallest of the major structural proteins of SARS-CoV-2 and participates in viral assembly and budding. During the replication cycle, E is abundantly expressed inside the infected cell, but only a small portion is incorporated into the virion envelope. The majority of the protein is localised at the site of intracellular trafficking.(3) We currently offer two E-protein antibodies SARS-CoV-2 E-protein antibody ABIN1031551 and SARS-CoV-2 E-protein antibody ABIN6952904 .
Below you will find the available SARS-CoV-2 Envelope protein antibodies. Click on the links to see more details.
SARS-CoV-2 Membrane Protein Antibodies
The coronavirus membrane (M) protein is the key player in virion assembly. One of its functions is to mediate the incorporation of the spikes into the viral envelope. When expressed alone, it accumulates in the Golgi complex in homomultimeric complexes. However, in combination with the E protein, virus-like particles (VLPs) similar to authentic virions in size and shape are assembled, demonstrating that the M and E proteins are the minimal requirements for envelope formation.(4)
SARS-CoV-2 ORF Antibodies
Neutralizing SARS-CoV-2 Antibody [CR3022]
Presently, we are offering a variety of recombinant NAbs against SARS-CoV-2 S1, based on clone CR3022. Click the link below to see all available CR3022 antibodies.
- Recombinant human neutralizing antibody against SARS-CoV-2.
- Frequently used as reference in S-protein ELISAs and neutralization assays.
- Binds a highly conserved epitope, not interefering with the S-protein
- The chimeric SARS-CoV-2 S1 antibody (CR3022) binds the amino acids 318-510 in the S1 domain of the SARS-CoV-2 Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein.
- Epitope does not overlap with ACE2-Binding Site.
- 7 PubMed References available.
References: "Immune-mediated approaches against COVID-19." in: Nature nanotechnology, Vol. 15, Issue 8, pp. 630-645, (2020) (PubMed).
: "Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics." in: Molecular neurobiology, Vol. 57, Issue 10, pp. 4106-4116, (2020) (PubMed).
: "Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis." in: EXCLI journal, Vol. 19, pp. 410-417, (2020) (PubMed).
: "Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. ..." in: Nature, (2020) (PubMed).
: "Biochemical characterization of SARS-CoV-2 nucleocapsid protein." in: Biochemical and biophysical research communications, Vol. 527, Issue 3, pp. 618-623, (2020) (PubMed).
: "Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein." in: Journal of virology, Vol. 73, Issue 9, pp. 7441-52, (1999) (PubMed).
: "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding." in: Lancet (London, England), Vol. 395, Issue 10224, pp. 565-574, (2020) (PubMed).
Goal-oriented, time line driven scientist, proficiently trained in different academic institutions in Germany, France and the USA. Experienced in the life sciences e-commerce environment with a focus on product development and customer relation management.Go to author page